Life sciences news roundup: $175M for cell therapy; vaccine data; and more - GeekWire

2022-03-31 01:48:17 By : Mr. Chang Zhili

by Charlotte Schubert on March 26, 2022 at 7:00 amMarch 28, 2022 at 12:17 pm

It was another busy week in Seattle-area biotech.

Affini-T Therapeutics on Monday announced $175 million in initial financing. The company aims to move cell therapies developed at Fred Hutchinson Cancer Research Center into the clinic to treat solid tumors.

The week ended with Icosavax posting data “below our expectations” on its COVID-19 vaccine, sending shares sinking.

Meanwhile, HDT Bio’s COVID-19 vaccine may be slowed for a different reason. The Seattle startup filed a lawsuit against its India-based vaccine partner, claiming that it stole its tech and refused to share clinical trial data. HDT Bio’s early trials in other countries continue.

Finally, the University of Washington’s Institute for Protein Design continues to invent new ways to make drugs. Read on for their latest study, and other news from the Pacific Northwest — including a list of digital startups in the mental health field.  

— Fred Hutch spinout Affini-T Therapeutics lands $175M for cell therapies to treat solid tumors

— Icosavax posts COVID-19 vaccine data ‘below our expectations’ as shares plummet more than 60%

— Seattle startup claims India-based drugmaker stole COVID-19 vaccine tech, seeks $950M

— Univ. of Washington researchers find new way to design potential therapeutics

— A list of mental health startups in the Pacific Northwest, as pandemic fuels growth for sector

— Startup that aims to prevent tissue adhesions after surgery wins inaugural Apis health competition

Subscribe to GeekWire's free newsletters to catch every headline

Have a scoop that you'd like GeekWire to cover? Let us know.

Seattle startup claims India-based drugmaker stole COVID-19 vaccine tech, seeks $950M

Seattle startup HDT Bio raises $3M to support development of COVID-19 vaccine

DoD gives $1.1M to Seattle startup that will help find new antibodies against COVID-19 variants

Seattle’s HDT Bio to start U.S. clinical trials of its COVID-19 vaccine candidate

Elon Musk, are you out there? SpaceX Starlink internet service gets more reliable, and mobile

Award-winning Getty photographer turns lens on Seattle to illustrate problems gripping many cities

Researchers develop reactor that refines waste carbon into chemicals while generating hydrogen

Seattle-area population declined by 20,000 people in 2021 as remote work took hold

Catch every headline in your inbox